FDA Suspends UCART123 Trials After Patient Death – Immuno-Oncology News
|
FDA Suspends UCART123 Trials After Patient Death
Immuno-Oncology News The U.S. Food and Drug Administration (FDA) has suspended two Phase 1 trials assessing Cellectis' CAR T-cell therapy UCART123 in acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm (BPDCN) after the first patient died. |
